Page 21 - கடுமையான முதலீட்டாளர் உறவுகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/  GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company s lead therapeutic candidate, GTB-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). Reduction in Bone Marrow Blast Levels Achieved To date, 9 patients have been enrolled in the Phase I/II Expansion clinical trial. Patients enrolled early in the Study (patients 1-4) were treated with doses of GTB-3550 below the anticipated therapeutic dose (RP2D) and maximum tolerated dose (MTD) to address possible safety concerns.  All patients treated at the lower doses exhibited no signs of toxicity, and did no

United statesJulie seidelAnthony cataldoDavid castanedaBeverly hillsSusan roushStern investor relations incNational cancer instituteSource gt biopharma incExchange commissionUniversity of minnesotaGt biopharma incBone marrow blast levelsCytokine release syndromeMaximum tolerated doseClin cancer